Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
about
Hepatitis C virus: A time for decisions. Who should be treated and when?The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-AnalysisValue of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceWill Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World DataVirologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus.Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysisImpact of all oral anti-hepatitis C virus therapy: A meta-analysis.Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United StatesCost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approachCost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the NetherlandsEstimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China.Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in KoreaCost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C.Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionThe global burden of liver disease: the major impact of ChinaAccessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United StatesEconomic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis.Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection.Hepatitis C, disease and its management: a cost-effectiveness analysis of the new generation oral protease inhibitorsHIV-hepatitis C virus co-infection in the era of direct-acting antivirals.Simeprevir: a review of its use in patients with chronic hepatitis C virus infection.Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals.Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection.Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies.Potential market size and impact of hepatitis C treatment in low- and middle-income countries.From HCV To HBV Cure.Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study.Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties.Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.Novel symmetrical phenylenediamines as potential anti-hepatitis C virus agents.Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease.
P2860
Q26768274-A2AA6C41-8832-4CF6-8DA7-9ACB482AD4C7Q26777560-837D9632-1356-4EC0-BDA0-7C59E66DCBF2Q28072257-428D5EC2-06D8-42F5-94E3-A0C8397C4296Q28550101-3E6AB31A-E006-41F1-ACAF-DC2A2FDD54D5Q33419423-0B8F5E33-5840-4764-9C05-E945405984ECQ33672648-F622FF98-AA3F-4C09-BF4E-1A5A2387FA24Q33894256-B925D63C-FC2B-4DD1-BD1F-8BCF3C809446Q34452419-606FB056-9BDC-4976-A983-927BBE533F78Q35370579-DAC568F3-733B-4E38-B33F-EC578FCC3C84Q35501259-4EE9EB94-2D58-4890-AE5C-03D763716EF9Q35619161-AE69E1BF-64A4-42B1-900B-268F88ED5A3FQ35724374-3592A2D6-A5E5-407D-8B3C-F53DB6C4B787Q36155257-A4652724-0701-43C6-AA8A-2AF63AE1D5FEQ36336005-E1CFE6A5-C425-4090-94CB-D67C0A11FA92Q36460249-2857AB0D-E34C-4A8D-B21F-D0CDC635231EQ36479439-8FEC8CE4-5165-486D-AB5D-E18DB9DCA710Q36505470-1B30C44F-C3B5-4B39-B27A-708D1779D462Q36901892-0D5909B7-E08C-4D7A-A281-7FD3B7C543EFQ37018850-07C2F949-0C4D-4AA9-B25E-17B7F4ADBBEFQ37027342-75CFD178-F7C4-4935-9F5A-8BF505F1BE97Q37098646-4A9195AC-FD70-437E-A45E-3ADC329F057FQ37484155-1DCEE4B1-0DD5-4CD7-A5D6-A27E1614B0D3Q37629097-C1C811D9-CDC3-40D2-8256-FAA34006CFDBQ37662061-2E5D40D6-64A2-49D1-88D1-B77B78904F12Q38226460-D0DD19A3-05D3-476C-BDF1-86F5C20580E9Q38307580-CC1DA74B-D72A-4944-8209-3C8972597A18Q38375284-B640ECE3-1F56-4ADC-9E58-B54BB6D3A0D1Q38470584-D98A478F-BB25-4275-B507-6B3D66F8753DQ38517530-7AFAFB5E-021D-41FA-B0F1-29418961BB2CQ38691333-713BF97F-EFCF-4B09-AFA4-B86ED2CE29DEQ38755073-3E6AF3BE-5E72-4E09-872F-6ADAC33CADEFQ38800572-A3E1E605-4F46-43BA-9C86-89E722DA5501Q38902281-5562E8B2-5B45-4199-AB8C-D86C15C7C445Q39067338-90073330-2A59-416B-AD13-ACE95C5AC78EQ39462995-561BF7D8-ADDE-47B8-9AF6-2CB5F6F41E02Q40035445-F2D6E286-4093-4087-BA21-2169060D2AAAQ40228338-01611363-50C0-4894-8F7E-277CA54C5C07Q40420373-A3BBB37E-2B16-4496-820D-FADECA18D55CQ40463230-0912F86E-688A-4BE4-91EF-897151A6F520Q40597591-FFC0A4D6-D231-49D7-A378-2044CEAA9B4C
P2860
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Cost analysis of sofosbuvir/ri ...... igible/intolerant individuals.
@ast
Cost analysis of sofosbuvir/ri ...... igible/intolerant individuals.
@en
type
label
Cost analysis of sofosbuvir/ri ...... igible/intolerant individuals.
@ast
Cost analysis of sofosbuvir/ri ...... igible/intolerant individuals.
@en
prefLabel
Cost analysis of sofosbuvir/ri ...... igible/intolerant individuals.
@ast
Cost analysis of sofosbuvir/ri ...... igible/intolerant individuals.
@en
P2860
P356
P1433
P1476
Cost analysis of sofosbuvir/ri ...... igible/intolerant individuals.
@en
P2093
Liesl M Hagan
Mark S Sulkowski
P2860
P356
10.1002/HEP.27151
P407
P577
2014-05-14T00:00:00Z